Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

ClinicalTrials.gov ID: NCT00069745

Public ClinicalTrials.gov record NCT00069745. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-National Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients With Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

PURPOSE: The SPARC trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and prednisone, versus prednisone alone as second line chemotherapy in patients with hormone-refractory prostate cancer (HRPC). TARGET PATIENT POPULATION: The SPARC trial is intended for patients who have hormone-refractory prostate cancer (HRPC) and whose disease has progressed after treatment with one chemotherapy regimen. Please refer to the Eligibility Criteria page for the key inclusion and exclusion criteria. WHAT IS SATRAPLATIN: Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally. Satraplatin is also the only platinum-based drug that has demonstrated efficacy against prostate cancer in a randomized trial. RATIONALE: There are currently no approved chemotherapy drugs for the second line treatment of hormone-refractory prostate cancer (HRPC). In a preliminary randomized trial conducted in Europe, the combination of satraplatin and prednisone had superior activity compared to prednisone alone, for the treatment of HRPC patients who had not previously been treated with chemotherapy

Study identification

NCT ID
NCT00069745
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Agennix
Industry
Enrollment
Not listed

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2003
Primary completion
Dec 31, 2005
Completion
Feb 28, 2007
Last update posted
Aug 6, 2012

2003 – 2007

United States locations

U.S. sites
105
U.S. states
32
U.S. cities
93
Facility City State ZIP Site status
Birmingham Hematology and Oncology Birmingham Alabama 35205
Birmingham Hematology and Oncology Birmingham Alabama 35235
Hematology Oncology Associates Phoenix Arizona 85012
Northern AZ Hematology & Oncology Assoc. Sedona Arizona 86336
Hematology Oncology Physicians/SMO Tucson Arizona 85712
Arizona Cancer Center Tuscon Arizona 85724
California Cancer Center Fresno California 93720
Pacific Shores Medical Group Long Beach California 90813
Division of Hematology - Oncology Los Angeles California 90095-7187
University of California Davis Cancer Center, Division of Hematology-Oncology Sacramento California 95817
Sharp Healthcare - Clinical Oncology Research San Diego California 92123
Rocky Mountain Cancer Center - Midtown Denver Colorado 80218
Hartford Hospital Hartford Connecticut 06102
DeQuattro Community Cancer Center Manchester Connecticut 06040
Cancer Centers of Florida-Altamonte Altamonte Springs Florida 34761
The Center for Hematology Oncology Boca Raton Florida 33486
Hematology/Oncology Group of South Florida Miami Florida 33176
Innovative Medical Research of South Florida Miami Shores Florida 33179
Florida Cancer Institute New Port Richey Florida 34655
Ocala Oncology Center Ocala Florida 34474
South Florida Oncology & Hematology Plantation Florida 33324
Hematology/Oncology Associates of Treasure Coast Port Saint Lucie Florida 34952
Oncology and Hematology Associates of West Broward P.A. Tamarac Florida 33321
Decatur Memorial Hospital Decatur Illinois 62526
Northwest Medical Specialists Niles Illinois 60714
North Shore Research Association Skokie Illinois 60076
Central Indiana Cancer Centers Fishers Indiana 46227
Indiana Hematology Oncology Consultants Indianapolis Indiana 46202
Central Indiana Cancer Centers Indianapolis Indiana 46227
Oncology Associates of Cedar Rapids Cedar Rapids Iowa 52403
Kansas City Cancer Centers - Southwest Overland Park Kansas 66210
Louisiana Oncology Associates Lafayette Louisiana 70506
LSU Health Science Center, Stanley S. Scott Cancer Center New Orleans Louisiana 70112
Maine Center for Cancer Medicine & Blood Disorders Scarborough Maine 04074
Berkshire Hematology Oncology Pittsfield Massachusetts 01201
Karmanos Cancer Institute, Wayne State University Detroit Michigan 48201
Maplewood Cancer Center Maplewood Minnesota 55404
Virginia Piper Cancer Institute Minneapolis Minnesota 55407
Missouri Cancer Associates Columbia Missouri 65201
Capitol Comprehensive Cancer Care Clinic Jefferson City Missouri 65109
St. Joseph Oncology, Inc. Saint Joseph Missouri 64507
Hematology/Oncology Consultants, Inc. St Louis Missouri 63136
Arch Medical Services, Inc. Washington Missouri 63090
Nebraska Methodist Hospital Cancer Center Omaha Nebraska 68114
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89109
Nevada Cancer Institute Las Vegas Nevada 89135
New Hampshire Oncology-Hematology PA Hooksett New Hampshire 03106
Hematology Oncology Associates Albuquerque New Mexico 87106
Lovelace Sandia Health Systems Albuquerque New Mexico 87108
Veterans Affairs Medical Center Albuquerque New Mexico 87108
The University of New Mexico Albuquerque New Mexico 87131-0001
New Mexico Cancer Care Associates Santa Fe New Mexico 87505
Albany Regional Cancer Center Albany New York 12208
New York Oncology Hematology, P.C. Albany New York 12208
Advanced Oncology Associates Armonk New York 10504
Roswell Park Cancer Institute Buffalo New York 14263
Interlakes Oncology Hematology Canandaigua New York 14623
Columbia Presbyterian Medical Center New York New York 10032
New York Oncology Hematology Rexford New York 12148
VA Medical Center Syracuse Syracuse New York 13210
Raleigh Hematology Oncology Clinic Cary North Carolina 27511
Piedmont Hematology - Oncology Winston-Salem North Carolina 27103
Dayton Oncology Hematology Kettering Ohio 45067
Cancer Care Associates Oklahoma City Oklahoma 73120
Cancer Care Associates Tulsa Oklahoma 74136
Willamette Valley Cancer Center Eugene Oregon 97401
Hematology and Oncology Associates of Northeastern PA / PC Dunmore Pennsylvania 18512
University of Pennsylvania Abramson Cancer Center Philadelphia Pennsylvania 19104
University of Pittsburgh Cancer Institute- Hillman Cancer Center Pittsburgh Pennsylvania 15232
Charleston Cancer Center Charleston South Carolina 29406
Medical University of South Carolina Hollings Cancer Center Charleston South Carolina 29425
Cancer Center of the Carolinas, Seneca Seneca South Carolina 29672
The West Clinic Memphis Tennessee 38120
Texas Cancer Center Abilene Texas 79606
Texas Oncology Arlington Texas 76012
Southwest Regional Cancer Center Austin Texas 78705
Texas Oncology Cancer Center Austin Texas 78731
Mamie McFaddin Ward Cancer Center Beaumont Texas 77702
Texas Onoclogy PA - Bedford Bedford Texas 76022
Texas Cancer Center at Medical City Dallas Texas 75230
Texas Oncology, P.A. Dallas Texas 75231-1449
The Texas Cancer Center Dallas Texas 75237
TOPA Sammons Cancer Center Dallas Texas 75246
Texas Cancer Center Denton Texas 76210
El Paso Cancer Treatment Center El Paso Texas 79915
Texas Oncology, P.A. Fort Worth Texas 76104
San Antonio Tumor & Blood Clinic Fredericksburg Texas 78624
Texas Oncology, P.A. Garland Texas 75042
Texas Oncology, P.A. - Irving Irving Texas 75601
Lake Vista Cancer Center Lewisville Texas 75067
Longview Cancer Center Longview Texas 75601
S. Texas Cancer Center McAllen Texas 78503
Texas Cancer Center of Mesquite Mesquite Texas 75150
Allison Cancer Center Midland Texas 79701
West Texas Cancer Center Odessa Texas 79761
Hematology Oncology Associates of South Texas San Antonio Texas 78229
Tyler Cancer Center Tyler Texas 75702
Waco Cancer Care Research Center Waco Texas 76712
Texas Oncology, P.A. - Deke Slayton Cancer Center Webster Texas 77598
Virginia Oncology Associates Norfolk Virginia 23501
Onc and Hem Associates of SW VA, Inc. Salem Virginia 24153
Puget Sound Cancer Center - Edmonds Edmonds Washington 98026
Cancer Care Northwest-North Spokane Washington 99218
Northwest Cancer Specialists Vancouver Washington 98684
Froedtert Memorial Lutheran Hospital Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 106 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00069745, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 6, 2012 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00069745 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →